Peng-Jun Lu1, Walter W Williams2, Jun Li3, Christina Dorell2, David Yankey2, Deanna Kepka4, Eileen F Dunne5. 1. Immunization Services Division, National Center for Immunization and Respiratory Diseases, CDC, Atlanta, Georgia. Electronic address: lhp8@cdc.gov. 2. Immunization Services Division, National Center for Immunization and Respiratory Diseases, CDC, Atlanta, Georgia. 3. Division of Cancer Prevention and Control, National Center for Chronic Disease Prevention and Health Promotion, CDC, Atlanta, Georgia. 4. Division of Cancer Control and Population Sciences, National Cancer Institute, Bethesda, Maryland. 5. Division of Sexually Transmitted Disease Prevention, National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention, CDC, Atlanta, Georgia.
Abstract
BACKGROUND: In 2009, the quadrivalent human papillomavirus (HPV) vaccine was licensed by the U.S. Food and Drug Administration for use in men/boys aged 9-26 years. In 2009, the Advisory Committee on Immunization Practices (ACIP) provided a permissive recommendation allowing HPV vaccine administration to this group. PURPOSE: To assess HPV vaccination initiation and coverage, evaluate awareness of HPV and HPV vaccine, and identify factors independently associated with such awareness among men aged 18-26 years. METHODS: Data from the 2010 National Health Interview Survey were analyzed in 2011. RESULTS: In 2010, HPV vaccination initiation among men aged 18-26 years was 1.1%. Among the 1741 men interviewed in this age group, nearly half had heard of HPV (51.8%). Overall, about one third of these men had heard of the HPV vaccine (34.8%). Factors independently associated with a higher likelihood of awareness of both HPV and HPV vaccine among men aged 18-26 years included having non-Hispanic white race/ethnicity; a higher education level; a U.S. birthplace; more physician contacts; private health insurance; received other vaccines; and reported risk behaviors related to sexually transmitted diseases, including HIV. CONCLUSIONS: HPV vaccination initiation among men aged 18-26 years in 2010 was low. HPV and HPV vaccine awareness were also low, and messages in this area directed to men are needed. Since ACIP published a recommendation for routine use of HPV4 among men/boys in December 2011, continued monitoring of HPV vaccination uptake among men aged 18-26 years is useful for evaluating the vaccination campaigns, and planning and implementing strategies to increase coverage. Published by Elsevier Inc.
BACKGROUND: In 2009, the quadrivalent human papillomavirus (HPV) vaccine was licensed by the U.S. Food and Drug Administration for use in men/boys aged 9-26 years. In 2009, the Advisory Committee on Immunization Practices (ACIP) provided a permissive recommendation allowing HPV vaccine administration to this group. PURPOSE: To assess HPV vaccination initiation and coverage, evaluate awareness of HPV and HPV vaccine, and identify factors independently associated with such awareness among men aged 18-26 years. METHODS: Data from the 2010 National Health Interview Survey were analyzed in 2011. RESULTS: In 2010, HPV vaccination initiation among men aged 18-26 years was 1.1%. Among the 1741 men interviewed in this age group, nearly half had heard of HPV (51.8%). Overall, about one third of these men had heard of the HPV vaccine (34.8%). Factors independently associated with a higher likelihood of awareness of both HPV and HPV vaccine among men aged 18-26 years included having non-Hispanic white race/ethnicity; a higher education level; a U.S. birthplace; more physician contacts; private health insurance; received other vaccines; and reported risk behaviors related to sexually transmitted diseases, including HIV. CONCLUSIONS:HPV vaccination initiation among men aged 18-26 years in 2010 was low. HPV and HPV vaccine awareness were also low, and messages in this area directed to men are needed. Since ACIP published a recommendation for routine use of HPV4 among men/boys in December 2011, continued monitoring of HPV vaccination uptake among men aged 18-26 years is useful for evaluating the vaccination campaigns, and planning and implementing strategies to increase coverage. Published by Elsevier Inc.
Authors: Djenaba A Joseph; Jacqueline W Miller; Xiaocheng Wu; Vivien W Chen; Cyllene R Morris; Marc T Goodman; Jose M Villalon-Gomez; Melanie A Williams; Rosemary D Cress Journal: Cancer Date: 2008-11-15 Impact factor: 6.860
Authors: Jessica Hughes; Joan R Cates; Nicole Liddon; Jennifer S Smith; Sami L Gottlieb; Noel T Brewer Journal: Cancer Epidemiol Biomarkers Prev Date: 2009-02-03 Impact factor: 4.254
Authors: D Brad Rindal; Gregg H Gilbert; Claudia Carcelén; Ellen Funkhouser; Emily Durand; David A Uppgaard; Jeff Fellows; Jana Ikeda; Alexander Ross Kerr; Branden Brar; Valeria V Gordan; Sudhir Agarwal; Peter Barnett; Robert K Pickard; Maura Gillison Journal: J Am Dent Assoc Date: 2019-02 Impact factor: 3.634
Authors: Peng-Jun Lu; Alfonso Rodriguez-Lainz; Alissa O'Halloran; Stacie Greby; Walter W Williams Journal: Am J Prev Med Date: 2014-10-07 Impact factor: 5.043
Authors: María Inmaculada Rodríguez-Álvarez; Jose L Gómez-Urquiza; Husein Husein-El Ahmed; Luis Albendín-García; Juan Gómez-Salgado; Guillermo A Cañadas-De la Fuente Journal: Int J Environ Res Public Health Date: 2018-10-10 Impact factor: 3.390